UCB S.A.

UCB, based in Brussels, is a biopharmaceutical company focused on severe diseases in immunology and neurology, with treatments for epilepsy, psoriasis, rheumatoid arthritis and other conditions, led by newer medicines such as Bimzelx. A pipeline of specialty drugs gives it a growing, higher-margin base as older products face competition. UCB has paid and gradually raised its dividend for many years without a cut, funded by dependable drug sales, which earns it a solid DiviScore. A reliable, growing yield backed by a focused specialty-pharma business defines its income appeal, though the modest yield reflects reinvestment in research.